New malaria vaccine schedule trial aims to protect infants
NCT ID NCT06879327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the R21/Matrix-M malaria vaccine in about 964 African infants to find the best timing for shots. Researchers compare a compressed schedule (6, 10, 14 weeks) with relaxed schedules (2, 4, 6 months or 3, 6, 9 months) to see which works best with other routine vaccines. The goal is to improve protection against malaria in young children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe de Recherche Action en Santé (GRAS)
RECRUITINGOuagadougou, Burkina Faso
-
Institut de Recherche en Sciences de la Santé (IRSS)
RECRUITINGBobo-Dioulasso, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.